

Qingyun Ren,<sup>a\*</sup> ShiYan Xia,<sup>b</sup> Yucheng Gu,<sup>c,a</sup> Baoju Li,<sup>b</sup> and Hongwu He<sup>a\*</sup>

<sup>a</sup>Key Laboratory of Pesticide and Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, 152 Luoyu Road, Wuhan, 430079, China

<sup>b</sup>Institute of Vegetables and Flowers, Chinese Academy of Agricultural Sciences, Beijing, 100081, China


<sup>c</sup>Syngenta Jealott's Hill International Research Centre, Bracknell., Berkshire RG42 6EY, United Kingdom

\*E-mail: ren0227@gmail.com; he1208@ccnu.edu.cn

Received April 30, 2013

DOI 10.1002/jhet.2119

Published online 00 Month 2014 in Wiley Online Library (wileyonlinelibrary.com).



Fifteen novel 2-alkylamino-3-aryl-8-cyano-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones **6a–6o** were designed and have been successfully synthesized via tandem aza-Wittig and annulation reactions with the corresponding iminophosphoranes **4**, aryl isocyanate, and amines in good yields. Their structures were clearly verified by IR spectroscopy, <sup>1</sup>H-NMR spectroscopy, EI-MS, and elemental analysis, and in the case of compound **6i**, further analyzed by single-crystal X-ray diffraction. The preliminary results of an *in vivo* bioassay showed that some compounds display moderate antifungal activity.

*J. Heterocyclic Chem.*, **00**, 00 (2014).

## INTRODUCTION

Derivatives of pyridopyrimidines have been the focus of great interest over many years. This is due to the wide range of biological activities associated with heterocyclic scaffold. Some of these compounds have shown remarkable biological properties such as antitumor, antiviral, antibacterial, antihypertensive, antibronchitis, antiallergic, antiarthritic, and anti-HIV activities [1–7], whereas others exhibited good insecticidal, growth regulatory, herbicidal, and fungicidal activities [8–10]. For example, some related 4-(phenylamino) pyrido[*d*]pyrimidines have been reported as selective inhibitors of tyrosine phosphorylation by the epidermal growth-factor receptor and have become an important class of potential anticancer drugs [1,2].


The pyrido[2,3-*d*]pyrimidine system has been studied in more detail, because examples have medicinal applications as inhibitors of tyrosine kinase [11] or dihydrofolate reductase [11,12]. However, few reports [1,13] are available so far to the preparation of pyrido[4,3-*d*]pyrimidine derivatives, which are of considerable interest as potential biologically active compounds or pharmaceuticals. The methods described so far for the preparation of some representative derivatives of this ring system involve two general routes [1–16]: (a) formation of the pyridine ring by cyclization of suitable substituents of a pyrimidine and (b) formation of the pyrimidine ring by cyclization of a suitable pyridine derivative. However, these methods often require forcing conditions, long reaction times, and complex synthetic pathways.

For the reason given earlier, the synthesis of pyrido[4,3-*d*]pyrimidine derivatives is challenging. The aza-Wittig reactions of iminophosphoranes have recently received

increasing attention in view of their utility in the synthesis of *N*-heterocyclic compounds [17]. Previously, we had designed and synthesized fused pyrimidine derivatives such as thiazolopyrimidinones [18], thienopyrimidinones [19], and triazolopyrimidinones [20] prepared from various iminophosphoranes, and it was found that these novel fused pyrimidines compounds displayed good antifungal activity against *Rhizoctonia solani*. As a continuation of our ongoing project related to the discovery and optimization of pesticide leads, we would like to describe a facile synthesis of novel pyrido[4,3-*d*]pyrimidine derivatives via the tandem aza-Wittig and cyclization reaction. The preliminary results of an *in vivo* bioassay indicated that some of these compounds display moderate antifungal activity.

## RESULTS AND DISCUSSION


The intermediate **1** was prepared by the reaction of malononitrile and carbon bisulfide in the presence of KOH as base in acetonitrile and then treated with ammonium hydroxide in ethanol [21]. It was reported that 4-aminonicotinonitrile **3** was prepared from reaction of ketene *N,S*-acetal **1** with ethyl acetoacetate **2** in moderate yield (48%) by using anhydrous stannic chloride as catalyst [22]. Herein, we investigated the effects of a variety of catalysts such as zinc chloride, ferric chloride, zinc nitrate, and zinc acetate instead of anhydrous stannic chloride on the reaction. Zinc nitrate was finally selected as catalyst, and much higher yield (95%) was achieved (Scheme 1). Optimization of the reaction conditions and the detailed mechanism using zinc nitrate as catalyst were further elucidated in our published paper [23].

**Scheme 1.** Synthesis of 4-aminonicotinonitrile **3**.

Compound **3** was further converted to iminophosphorane **4** via reaction with triphenylphosphine, hexachloroethane, and triethylamine in good yield. Iminophosphorane **4** reacted with aromatic isocyanates and gave carbodiimides **5**. In refluxing toluene, the direct reaction of carbodiimides **5** with alkylamines did not react to give the target compounds **6**. However, when the solvent was changed to  $\text{CH}_2\text{Cl}_2$  and in the presence of a catalytic amount of  $\text{EtONa/EtOH}$ , compound **5** was converted smoothly to the 2-alkylamino-pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones **6** in satisfactory yields at room temperature (Scheme 2, Table 1).

It is worth noting that the reaction between carbodiimides **5** and primary amines obtained mainly 2-


alkylamino-pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones **6**, and another kind of cyclization compound 2-arylamino-pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones **8** were not found (Scheme 3). This might be due to the geometry of the guanidine intermediate and the conjugative effect of compounds **6**. As the amines were reacted with **5**, intermediates **7a** were formed because the amines would attack **5** mainly from the opposite direction of the  $\text{CO}_2\text{Et}$  group because of the group's steric hindrance. At the same time, the compounds **6** are more stable than compounds **8** because of the conjugative effect between the pyridopyrimidine ring and the phenyl ring. Therefore, only compounds **6** were obtained regioselectively.

**Scheme 2.** Synthesis of 2-alkylamino-pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones **6**.

**Table 1**  
Synthesis of compound **6**.


Compounds	RNH	Ar	Yield (%) <sup>a</sup>	Compounds	RNH	Ar	Yield (%) <sup>a</sup>
<b>6a</b>	PrNH	4-FPh	76	<b>6i</b>	BuNH	4-ClPh	82
<b>6b</b>	BuNH	4-FPh	86	<b>6j</b>	Cyclohexylamino	4-ClPh	91
<b>6c</b>	<i>i</i> -BuNH	4-FPh	88	<b>6k</b>	2-ClPhCH <sub>2</sub> NH	Ph	85
<b>6d</b>	<i>t</i> -BuNH	4-FPh	91	<b>6l</b>	4-FPhCH <sub>2</sub> NH	Ph	81
<b>6e</b>	$\text{CH}_3(\text{CH}_2)_4\text{NH}$	4-FPh	85	<b>6m</b>	3-MePhCH <sub>2</sub> NH	Ph	87
<b>6f</b>	$\text{CH}_3(\text{CH}_2)_5\text{NH}$	4-FPh	78	<b>6n</b>	4-FPh CH <sub>2</sub> CH <sub>2</sub> NH	Ph	83
<b>6g</b>	Allylamino	4-FPh	87	<b>6o</b>	4-MeOPh CH <sub>2</sub> CH <sub>2</sub> NH	Ph	79
<b>6h</b>	PrNH	4-ClPh	83				

<sup>a</sup>Yields of isolated products based on iminophosphorane **4**.

**Scheme 3.** Possible mechanism of the formation of compounds **6**.

All the compounds of the **6** series were obtained as white solids after recrystallization from ethanol. Their structures were fully characterized by IR spectroscopy,  $^1H$ -NMR spectroscopy, EIMS, and elemental analysis. In the case of **6o**, the structure was additionally solved by single-crystal X-ray diffraction [24] (Figure 1). All structures were supported spectroscopically. For example, the IR spectra of **6l** revealed CN and C=O absorption bands at  $2216$  and  $1684\text{ cm}^{-1}$ , respectively; the signals attributable

to NH are found at  $3390\text{ cm}^{-1}$ . The corresponding  $^1H$ -NMR spectrum showed the 5-Me group at  $\delta(H)$  2.90 (s), and the  $CH_3$  signals of the SME appeared at  $\delta(H)$  2.69. The other signals resonated at  $\delta(H)$  6.97–7.65 (m, 9 arom. H), 4.63 (d,  $J=5.6\text{ Hz}$ ,  $CH_2$ ), and 4.89 (s, NH). The mass spectrum of **6l** showed the molecular ion peak at  $m/z$  431 as the base peak (100%). The structures of **6l** and the other analogs were further confirmed on the basis of elemental analysis.

**Figure 1.** Perspective view of the X-ray crystal structure of **6o**.

The preliminary antifungal activity of compounds **6** series was measured at a concentration of 500 mg/L using a reported procedure [25], and the *in vivo* inhibition rates are listed in Table 2. Fungicidal activities of commercial fungicides chlorothalonil, dimethomorph, and thiophanate methyl as a control against the five fungi mentioned in Table 2 were evaluated at the same condition. It was found that most of the compounds exhibited inhibitory activity against *Cladosporium cucumerinum* and *Phytophthora capsici*. They did have any obvious influence on the growth of *Corynespora cassiicola*, *R. solani*, and *Fusarium oxysporum*. Although the antifungal activity of these compounds are lower than that of commercial fungicides, the inhibitory activity of title compounds could be further improved by incorporating appropriate functional groups.

In summary, we have developed an efficient and convenient synthetic method for the preparation of pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones in good yield via tandem aza-Wittig reaction and annulation reactions. The preliminary results of an *in vivo* bioassay showed that some compounds display moderate antifungal activities, and further bioassay, optimization, and structure–activity relationships of the title compounds are underway.

## EXPERIMENTAL

Melting points were measured on an electrothermal melting point apparatus X-4(Beijing Tektronix Instrument Inc., Beijing, China) and uncorrected. Mass spectra were measured on a Finnigan Trace MS 2000 spectrometer (Thermo Finnigan, Silicon Valley, CA, USA). IR spectra were recorded on a NicoletAvatar 360 FT-IR spectrometer (Thermo Electron Inc., San Jose, CA, USA) as KBr pellets with absorption in  $\text{cm}^{-1}$ .  $^1\text{H}$ -NMR spectra

were recorded in  $\text{CDCl}_3$  on a Mercury Plus 400 MHz (Varian, Palo Alto, CA, USA), and resonances were given in parts per million ( $\delta$ ) relative to TMS ( $\delta$  0.00 ppm).  $^{13}\text{C}$ -NMR spectra were recorded using  $\text{CDCl}_3$  as the solvent on a Unity Inova 600 MHz (Varian), and resonances were given in parts per million ( $\delta$ ) relative to  $\text{CDCl}_3$  ( $\delta$  77.00 ppm). The elementary analysis was performed on a Vario EL III elementary analysis instrument (Elementar Analysensysteme GmbH, Germany). The X-ray single crystal diffractometer is Bruker Smart Apex CCD X-ray crystal (Elementar Analysensysteme GmbH). All of the solvents and materials were reagent grade and purified as required.

**Synthesis of 6-methylsulfanyl-4-amino-5-cyano-2-methyl-nicotinic acid ethyl esters **3**.** A mixture of 2-(methylsulfanyl-amino-methylene)-malononitrile **1** (10 mmol) and  $\text{Zn}(\text{NO}_2)_2 \cdot 6\text{H}_2\text{O}$  (20 mmol) were added to a stirred solution of ethyl acetoacetate **2** (20 mmol) in ethanol (30 mL). The solution was refluxed for 6–8 h and then cooled to room temperature. The crude precipitated product was collected by filtration. Further purification was accomplished by recrystallization from ethanol to give pure products of **3** in 95% yield. White solid, mp 136.0–138.0°C;  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ )  $\delta$  1.41 (t,  $J=7.2$  Hz, 3H,  $\text{OCH}_2\text{CH}_3$ ), 2.62 (s, 3H,  $\text{SCH}_3$ ), 2.70 (s, 3H,  $\text{py-CH}_3$ ), 4.39 (q,  $J=7.2$  Hz, 2H,  $\text{OCH}_2$ ), 6.68 ppm (s, 2H,  $\text{NH}_2$ ). MS:  $m/z$  252 ( $\text{M}^+ + 1$ , 23), 251 ( $\text{M}^+$ , 100), 250 ( $\text{M}^+ - 1$ , 41), 223 (47), 205 (31), 177(30); *Anal.* Calcd for  $\text{C}_{11}\text{H}_{13}\text{N}_3\text{O}_2\text{S}$ : C, 52.57; H, 5.21; N, 16.72; S, 12.76. Found: C, 52.75; H, 4.80; N, 16.89; S, 12.72.

**Synthesis of 6-methylsulfanyl-5-cyano-2-methyl-4-[(triphenylphosphanylidene)amino]-nicotinic acid ethyl esters **4**.** To a solution of **3** (2.51 g, 10 mmol) in MeCN (40 mL) were added  $\text{Ph}_3\text{P}$  (7.86 g, 30 mmol),  $\text{C}_2\text{Cl}_6$  (7.12 g, 30 mmol), and  $\text{Et}_3\text{N}$  (8.0 mL), in this order. The mixture was stirred for 6–7 h at rt. Then, the solution was concentrated, and the residue was recrystallized from EtOH to give **4** in 90% yield. mp 153–155°C.  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ )  $\delta$  1.09 (t,  $J=7.2$  Hz, 3H,  $\text{CH}_3$ ), 2.37 (s, 3H,  $\text{SCH}_3$ ), 2.51 (s, 3H,  $\text{py-CH}_3$ ), 3.95 (q,  $J=7.2$  Hz, 2H,  $\text{OCH}_2$ ), 7.44–7.71 ppm (m, 15H, Ph-H).

Table 2

Antifungal activity (relative inhibition (%), *in vivo*, 500 mg/L) of compound **6**.

Compounds	<i>Cladosporium cucumerinum</i>	<i>Corynespora cassiicola</i>	<i>Rhizoctonia solani</i>	<i>Phytophthora capsici</i>	<i>Fusarium oxysporum</i>
<b>6a</b>	44	50	54	3	0
<b>6b</b>	51	47	0	63	0
<b>6c</b>	21	19	0	54	0
<b>6d</b>	72	21	0	44	0
<b>6e</b>	58	46	0	49	0
<b>6f</b>	7	39	0	23	6
<b>6g</b>	65	3	37	68	28
<b>6h</b>	0	25	77	24	11
<b>6i</b>	69	46	0	46	0
<b>6j</b>	9	58	0	36	6
<b>6k</b>	37	0	0	58	17
<b>6l</b>	18	17	50	68	0
<b>6m</b>	25	38	31	71	6
<b>6n</b>	70	47	0	55	11
<b>6o</b>	40	29	0	39	6
Chlorothalonil	94	95	77		
Dimethomorph				98	
Thiophanatemethyl					90



**General procedure for the preparation of 2-alkylamino-3-aryl-8-cyano-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones (6a–6o).** To a solution of iminophosphorane **4** (0.51 g, 1 mmol) in dry methylene chloride (10 mL), aryl isocyanate (1.1 mmol) was added under nitrogen at room temperature. After the reaction mixture was left unstirred for 6–12 h, the solvent was removed under vacuum, and Et<sub>2</sub>O/petroleum ether (1:2, 20 mL) was added to precipitate triphenylphosphine oxide. Removal of the solvent gave carbodiimides **5**, which were used directly without further purification.

Alkylamine (1.1 mmol) was added into the solution of **5** prepared earlier in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). After the reaction mixture was stirred continuously for an additional 6 h, the solvent was removed, and 10 mL of anhydrous ethanol with several drops of sodium ethoxide in ethanol (3*M*) was added. After stirring for another 0.5–1 h, the solution was condensed, and the residue was recrystallized from dichloromethane/petroleum ether to give pure 2-alkylamino-3-aryl-8-cyano-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-ones (**6a–6o**).

**8-Cyano-3-(4-fluorophenyl)-5-methyl-7-(methylthio)-2-propylamino-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6a).** This compound was obtained as a white solid, mp 270.5–272.0°C, yield 0.29 g, 76%; IR (KBr): 3357, 2963, 2221 (CN), 1682 (C=O), 1584, 1559, 1508 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.88 (t, *J*=7.2 Hz, 3H, CH<sub>3</sub>), 1.55–1.60 (m, 2H, CH<sub>2</sub>), 2.67 (s, 3H, SCH<sub>3</sub>), 2.87 (s, 3H, py-CH<sub>3</sub>), 3.50–3.52 (m, 2H, NCH<sub>2</sub>), 4.46 (s, 1H, NH), 7.26–7.33 ppm (m, 4H, Ar-H). MS: *m/z* 385 (M<sup>+</sup>+2, 11), 384 (M<sup>+</sup>+1, 38), 383 (M<sup>+</sup>, 100), 382 (M<sup>+</sup>–1, 24), 355 (13), 340 (75), 325 (8), 95 (33), 75 (15), 41 (76); *Anal.* Calcd for C<sub>19</sub>H<sub>18</sub>FN<sub>5</sub>OS: C, 59.51; H, 4.73; N, 18.26. Found: C, 59.75; H, 4.54; N, 18.60.

**2-Butylamino-8-cyano-3-(4-fluorophenyl)-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6b).** This compound was obtained as a white solid, mp >280°C, yield 0.34 g, 86%; IR (KBr): 3344, 2951, 2222 (CN), 1682 (C=O), 1584, 1559, 1510 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO) δ 0.88 (t, *J*=7.2 Hz, 3H, CH<sub>3</sub>), 1.23–1.26 (m, 2H, CH<sub>2</sub>), 1.50–1.53 (m, 2H, CH<sub>2</sub>), 2.63 (s, 3H, SCH<sub>3</sub>), 2.78 (s, 3H, py-CH<sub>3</sub>), 3.32–3.36 (m, 2H, NCH<sub>2</sub>), 6.84 (s, 1H, NH), 7.41–7.44 ppm (m, 4H, Ar-H). MS: *m/z* 399 (M<sup>+</sup>+2, 4), 398 (M<sup>+</sup>+1, 38), 397 (M<sup>+</sup>, 30), 396 (M<sup>+</sup>–1, 14), 382 (31), 368 (14), 340 (50), 325 (9), 43 (100); *Anal.* Calcd for C<sub>20</sub>H<sub>20</sub>FN<sub>5</sub>OS: C, 60.44; H, 5.07; N, 17.62. Found: C, 60.95; H, 4.65; N, 18.00.

**8-Cyano-3-(4-fluorophenyl)-2-(iso-butylamino)-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6c).** This compound was obtained as a white solid, mp >280°C, yield 0.35 g, 88%; IR (KBr): 3374, 2930, 2220 (CN), 1682 (C=O), 1559, 1531 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.86 (d, *J*=6.8 Hz, 6H, 2\*CH<sub>3</sub>), 1.85–1.89 (m, 1H, CH), 2.68 (s, 3H, SCH<sub>3</sub>), 2.89 (s, 3H, py-CH<sub>3</sub>), 3.34–3.38 (m, 2H, NCH<sub>2</sub>), 4.48 (s, 1H, NH), 7.26–7.34 ppm (m, 4H, Ar-H). *Anal.* Calcd for C<sub>20</sub>H<sub>20</sub>FN<sub>5</sub>OS: C, 60.44; H, 5.07; N, 17.62. Found: C, 60.58; H, 4.63; N, 17.31.

**8-Cyano-3-(4-fluorophenyl)-5-methyl-7-(methylthio)-2-(tert-butylamino)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6d).** This compound was obtained as a white solid, mp 278.0–278.9°C, yield 0.36 g, 91%; IR (KBr): 3416, 2928, 2213 (CN), 1685 (C=O), 1564 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.45 (s, 9H, 3\*CH<sub>3</sub>), 2.68 (s, 3H, SCH<sub>3</sub>), 2.87 (s, 3H, py-CH<sub>3</sub>), 4.30 (s, 1H, NH), 7.29–7.32 ppm (m, 4H, Ar-H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ 13.1, 26.4, 28.8, 53.9, 98.5, 108.0, 114.9, 117.9, 118.2, 129.6, 130.7, 151.8, 157.7, 161.6, 164.6, 167.2 ppm; *Anal.* Calcd for C<sub>20</sub>H<sub>20</sub>FN<sub>5</sub>OS: C, 60.44; H, 5.07; N, 17.62. Found: C, 60.72; H, 4.61; N, 17.30.

**8-Cyano-3-(4-fluorophenyl)-5-methyl-7-(methylthio)-2-(pentylamino)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6e).** This compound was obtained as a white solid, mp 263.0–264.0°C, yield 0.35 g, 85%; IR (KBr): 3356, 2857, 2220 (CN), 1682 (C=O), 1558, 1508 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.87 (t, *J*=7.2 Hz, 3H, CH<sub>3</sub>), 1.23–1.32 (m, 4H, 2\*CH<sub>2</sub>CH<sub>2</sub>), 1.52–1.55 (m, 2H, CH<sub>2</sub>), 2.67 (s, 3H, SCH<sub>3</sub>), 2.88 (s, 3H, py-CH<sub>3</sub>), 3.50–3.53 (m, 2H, NCH<sub>2</sub>), 4.48 (s, 1H, NH), 7.30–7.33 ppm (m, 4H, Ar-H). *Anal.* Calcd for C<sub>21</sub>H<sub>22</sub>FN<sub>5</sub>OS: C, 61.29; H, 5.39; N, 17.02. Found: C, 61.20; H, 5.11; N, 16.76.

**8-Cyano-3-(4-fluorophenyl)-2-(hexylamino)-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6f).** This compound was obtained as a white solid, mp 162.0–164.0°C; yield 0.33 g, 78%; IR (KBr): 3366, 2929, 2220 (CN), 1683 (C=O), 1558, 1532 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.86 (t, *J*=6.4 Hz, 3H, CH<sub>3</sub>), 1.26–1.53 (m, 8H, 4\*CH<sub>2</sub>), 2.68 (s, 3H, SCH<sub>3</sub>), 2.89 (s, 3H, py-CH<sub>3</sub>), 3.50–3.53 (m, 2H, NCH<sub>2</sub>), 4.42 (s, 1H, NH), 7.29–7.35 ppm (m, 4H, Ar-H). *Anal.* Calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>5</sub>OS: C, 62.10; H, 5.68; N, 16.46. Found: C, 62.38; H, 5.35; N, 16.19.

**2-Allylamino-8-cyano-3-(4-fluorophenyl)-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6g).** This compound was obtained as a white solid, mp 285.0–286.0°C; yield 0.33 g, 87%; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 2.63 (s, 3H, SCH<sub>3</sub>), 2.78 (s, 3H, CH<sub>3</sub>), 3.93–3.96 (m, 2H, NCH<sub>2</sub>), 5.07 (d, *J*=10 Hz, 1H, CH), 5.17 (d, *J*=16.8 Hz, 1H, CH), 5.81–5.85 (m, 1H, CH), 7.07 (s, 1H, NH), 7.41–7.49 ppm (m, 4H, Ar-H). MS: *m/z* 382 (M<sup>+</sup>+1, 6), 381 (M<sup>+</sup>, 19), 380 (M<sup>+</sup>–1, 19), 366 (100), 348 (19), 340 (10), 204 (4), 190 (6), 135 (14); *Anal.* Calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>5</sub>OS: C, 59.83; H, 4.23; N, 18.36. Found: C, 60.10; H, 4.22; N, 17.91.

**3-(4-Chlorophenyl)-8-cyano-5-methyl-7-(methylthio)-2-propylamino-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6h).** This compound was obtained as a white solid, mp 235.0–238.0°C, yield 0.33 g, 83%; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.88 (t, *J*=7.2 Hz, 3H, CH<sub>3</sub>), 1.55–1.61 (m, 2H, CH<sub>2</sub>), 2.68 (s, 3H, SCH<sub>3</sub>), 2.89 (s, 3H, py-CH<sub>3</sub>), 3.51–3.53 (m, 2H, NCH<sub>2</sub>), 4.46 (s, 1H, NH), 7.25–7.63 ppm (m, 4H, Ar-H). MS: *m/z* 401 (M<sup>+</sup>+2, 37), 400 (M<sup>+</sup>+1, 26), 399 (M<sup>+</sup>, 96), 356 (100), 341 (9), 246 (7), 231 (8), 204 (10), 152 (21); *Anal.* Calcd for C<sub>19</sub>H<sub>18</sub>ClN<sub>5</sub>OS: C, 57.07; H, 4.54; N, 17.51. Found: C, 57.25; H, 4.56; N, 16.94.

**3-(4-Chlorophenyl)-8-cyano-2-butylamino-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6i).** This compound was obtained as a white solid, mp 233.0–234.0°C, yield 0.34 g, 82%; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.91 (t, *J*=7.2 Hz, 3H, CH<sub>3</sub>), 1.24–1.32 (m, 2H, CH<sub>2</sub>), 1.49–1.56 (m, 2H, CH<sub>2</sub>), 2.68 (s, 3H, SCH<sub>3</sub>), 2.88 (s, 3H, py-CH<sub>3</sub>), 3.53–3.55 (m, 2H, NCH<sub>2</sub>), 4.44 (s, 1H, NH), 7.25–7.63 ppm (m, 4H, Ar-H). MS: *m/z* 415 (M<sup>+</sup>+2, 8), 414 (M<sup>+</sup>+1, 26), 413 (M<sup>+</sup>, 100), 322 (34), 204 (52), 182 (55), 167 (67), 106 (31), 91 (65), 77(20); *Anal.* Calcd for C<sub>20</sub>H<sub>20</sub>ClN<sub>5</sub>OS: C, 58.03; H, 4.87; N, 16.92. Found: C, 58.12; H, 4.41; N, 16.61.

**3-(4-Chlorophenyl)-2-cyclohexylamino-8-cyano-5-methyl-7-(methylthio)-pyrido[4,3-*d*]pyrimidin-4(3*H*)-one (6j).** This compound was obtained as a white solid, mp >280°C, yield 0.40 g, 91%; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.06–1.36 (m, 4H, 2\*CH<sub>2</sub>), 1.38–1.47 (m, 2H, CH<sub>2</sub>), 1.59–1.62 (m, 2H, CH<sub>2</sub>), 1.97–1.99 (m, 2H, CH<sub>2</sub>), 2.68 (s, 3H, SCH<sub>3</sub>), 2.87 (s, 3H, CH<sub>3</sub>), 4.10–4.14 (m, 1H, CH), 4.26 (d, *J*=7.2 Hz, 1H, NH), 7.24–7.63 ppm (m, 4H, Ar-H). MS: *m/z* 441 (M<sup>+</sup>+2, 32), 440 (M<sup>+</sup>+1, 18), 439 (M<sup>+</sup>, 83), 358 (93), 356 (100), 341 (15), 247 (8), 192 (9), 177(6), 152(7); *Anal.* Calcd for C<sub>22</sub>H<sub>22</sub>ClN<sub>5</sub>OS: C, 60.06; H, 5.04; N, 15.92. Found: C, 59.84; H, 4.44; N, 15.47.

**2-(2-Chlorobenzylamino)-8-cyano-5-methyl-7-(methylthio)-3-phenyl-pyrido[4,3-d]pyrimidin-4(3H)-one (6k).** This compound was obtained as a white solid, mp 202.9–204.9°C, yield 0.38 g, 85%; IR (KBr): 3352, 2919, 2224 (CN), 1688 (C=O), 1557, 1532 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 2.68 (s, 3H, SCH<sub>3</sub>), 2.87 (s, 3H, py-CH<sub>3</sub>), 4.68 (d, *J*=6.4 Hz, 2H, NCH<sub>2</sub>), 5.31 (s, 1H, NH), 7.17–7.80 ppm (m, 9H, Ar-H). MS: *m/z* 450 (M<sup>+</sup>+3, 11), 449 (M<sup>+</sup>+2, 41), 448 (M<sup>+</sup>+1, 34), 447 (M<sup>+</sup>, 100), 446 (M<sup>+</sup>-1, 17), 412 (78), 322 (33), 140 (14); *Anal.* Calcd for C<sub>23</sub>H<sub>18</sub>ClN<sub>5</sub>OS: C, 61.67; H, 4.05; N, 15.63. Found: C, 61.84; H, 3.88; N, 15.24.

**8-Cyano-2-(4-fluorobenzylamino)-5-methyl-7-(methylthio)-3-phenyl-pyrido[4,3-d]pyrimidin-4(3H)-one (6l).** This compound was obtained as a white solid, mp 230.0–232.0°C, yield 0.35 g, 81%; IR (KBr): 3390, 2925, 2216 (CN), 1684 (C=O), 1556, 1529 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 2.69 (s, 3H, SCH<sub>3</sub>), 2.90 (s, 3H, py-CH<sub>3</sub>), 4.63 (d, *J*=5.6 Hz, 2H, NCH<sub>2</sub>), 4.89 (s, 1H, NH), 6.97–7.65 ppm (m, 9H, Ar-H). MS: *m/z* 433 (M<sup>+</sup>+2, 10), 432 (M<sup>+</sup>+1, 28), 431 (M<sup>+</sup>, 100), 430 (M<sup>+</sup>-1, 17), 322 (12), 185 (13); *Anal.* Calcd for C<sub>23</sub>H<sub>18</sub>FN<sub>5</sub>OS: C, 64.02; H, 4.20; N, 16.23. Found: C, 64.79; H, 3.98; N, 15.92.

**8-Cyano-5-methyl-2-(3-methylbenzylamino)-7-(methylthio)-3-phenyl-pyrido[4,3-d]pyrimidin-4(3H)-one (6m).** This compound was obtained as a white solid, mp 190.3–192.9°C, yield 0.37 g, 87%; IR (KBr): 3429, 2922, 2215 (CN), 1698 (C=O), 1581, 1540 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 2.33 (s, 3H, CH<sub>3</sub>), 2.68 (s, 3H, SCH<sub>3</sub>), 2.89 (s, 3H, py-CH<sub>3</sub>), 4.65 (d, *J*=5.6 Hz, 2H, CH<sub>2</sub>), 4.86 (s, 1H, NH), 7.07–7.64 ppm (m, 9H, Ar-H). MS: *m/z* 429 (M<sup>+</sup>+2, 9), 428 (M<sup>+</sup>+1, 29), 427 (M<sup>+</sup>, 100), 426 (M<sup>+</sup>-1, 16), 322 (14), 196 (33), 120 (32); *Anal.* Calcd for C<sub>24</sub>H<sub>21</sub>N<sub>5</sub>OS: C, 67.43; H, 4.95; N, 16.38. Found: C, 67.89; H, 4.77; N, 16.18.

**8-cyano-2-(4-fluorophenethylamino)-5-methyl-7-(methylthio)-3-phenyl-pyrido[4,3-d]pyrimidin-4(3H)-one (6n).** This compound was obtained as a white solid, mp 207.0–208.7°C, yield 0.37 g, 83%; IR (KBr): 3429, 2928, 2222 (CN), 1693 (C=O), 1557, 1535 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 2.69 (s, 3H, SCH<sub>3</sub>), 2.86 (t, *J*=7.2 Hz, 2H, CH<sub>2</sub>), 2.89 (s, 3H, py-CH<sub>3</sub>), 3.70–3.72 (m, 2H, NCH<sub>2</sub>), 4.46 (s, 1H, NH), 6.91–7.58 ppm (m, 9H, Ar-H). MS: *m/z* 447 (M<sup>+</sup>+2, 5), 446 (M<sup>+</sup>+1, 14), 445 (M<sup>+</sup>, 63), 425 (20), 322 (100), 307 (7), 122 (50); *Anal.* Calcd for C<sub>24</sub>H<sub>20</sub>FN<sub>5</sub>OS: C, 64.70; H, 4.52; N, 15.72. Found: C, 64.67; H, 4.17; N, 15.30.

**8-cyano-2-(3-methoxyphenethylamino)-5-methyl-7-(methylthio)-3-phenyl-pyrido[4,3-d]pyrimidin-4(3H)-one (6o).** This compound was obtained as a white solid, mp 185.5–188.5°C, yield 0.36 g, 79%; IR (KBr): 3412, 2931, 2219 (CN), 1689 (C=O), 1556, 1535 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 2.69 (s, 3H, SCH<sub>3</sub>), 2.85 (t, *J*=6.4 Hz, 2H, CH<sub>2</sub>), 2.90 (s, 3H, py-CH<sub>3</sub>), 3.72–3.75 (m, 2H, NCH<sub>2</sub>), 3.79 (s, 3H, OCH<sub>3</sub>), 4.47 (s, 1H, NH), 6.61–7.54 ppm (m, 9H, Ar-H). MS: *m/z* 459 (M<sup>+</sup>+2, 4), 458 (M<sup>+</sup>+1, 13), 457 (M<sup>+</sup>, 41), 322 (35), 307 (10), 134 (100), 91 (23), 77 (23); *Anal.* Calcd for C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S: C, 65.63; H, 5.07; N, 15.31. Found: C, 65.48; H, 4.97; N, 15.07.

**Acknowledgments.** The present work was supported by the National Basic Research Program of China (no. 2010CB126100) and the National Natural Science Foundation of China (no. 20772042, 21002037). The research was supported in part by the PCSIRT (no. IRT0953) and a studentship awarded to Qingyun Ren by Syngenta Ltd.

## REFERENCES AND NOTES

- [1] Rewcastle, W. G.; Palmer, D. B.; Thompson, A. M.; Bridges, A. J.; Cody, D. R. *J Med Chem* 1996, 39, 1823.
- [2] Smail, J. B.; Palmer, B. D.; Rewcastle, G. W. *J Med Chem* 1999, 42, 1803.
- [3] Broom, A. D.; Shim, J. L.; Anderson, G. L. *J Org Chem* 1976, 41, 1095.
- [4] Grivsky, E. M.; Lee, S.; Sigel, C. W.; Duch, D. S. *J Med Chem* 1980, 23, 327.
- [5] Huryn, D. M.; Okabe, M. *Chem Rev* 1992, 92, 1745.
- [6] Kuyper, L. F.; Garvey, J. M.; Baccanari, D. P.; Champness, J. N.; Stammers, D. K.; Beddell, C. R. *Bioorg Med Chem* 1996, 4, 593.
- [7] Joseph, I. D.; Pamela, H. G.; Willian, T. C.; Francis, M. S. *J Med Chem* 1992, 35, 320.
- [8] Heckler, R. E.; Jourdan, G. P. Eur. Patent 414386, February 27, 1991.
- [9] Rouchaud, J.; Neus, O.; Eelen, H. *Weed Res* 2002, 42, 14.
- [10] Yamada, H. Eur. Patent 665224, June 13, 1995.
- [11] (a) Boschelli, D.; Wu, Z.-P.; Klutchko, S. R.; Showalter, H. D. *J Med Chem* 1998, 41, 4365; (b) Jérôme A. *Tetrahedron* 2004, 60(18), 4107.
- [12] (a) Rosowsky, A.; Chen, H. *J Org Chem* 2001, 66, 7522; (b) DeGraw, J. I.; Christie, P. H.; Colwell, W. T.; Sirotinak, F. M. *J Med Chem* 1992, 35, 3204.
- [13] Ren, Q. Y.; Cui, Z. P.; He, H. W.; Gu, Y. C. *J Fluorine Chem* 2007, 128, 1369.
- [14] Bhuyan, P.; Boruah, R. C.; Sandhu, J. S. *J Org Chem* 1990, 55, 568.
- [15] Kajino, M.; Meguro, K. *Heterocycles* 1990, 31, 2153.
- [16] Hosmane, R. S.; Lim, B. B.; Summers, M. F.; Hosmane, N. S. *J Org Chem* 1988, 53, 5309.
- [17] Bonini, C.; Auria, M. D.; Funicello, M.; Romaniello, G. *Tetrahedron* 2002, 58, 3507.
- [18] Liang, Y.; Fan, S.; Mo, W. Y.; He, H. W. *J Fluorine Chem* 2007, 128(7), 879.
- [19] Ren, Q. Y.; Liang, Y. J.; He, H. W.; Fu, L. W.; Gu, Y. C. *Bioorg Med Chem Lett* 2009, 19, 6713.
- [20] Zhao, J. F.; Xie, C.; Ding, M. W.; He, H. W. *Chem Lett* 2005, 34, 1022.
- [21] Ren, Q. Y.; Mo, W. Y.; Gao, L.; He, H. W.; Gu, Y. C. *J Heteroc Chem* 2010, 47, 171.
- [22] Zhao, W. G.; Liu, Z. X.; Li, Z. M.; Wang, B. L. *Syn Commun* 2003, 33, 4229.
- [23] Ren, Q. Y.; Mo, W. Y.; Yao, Y. Y.; He, H. W.; Gu, Y. C. *Syn Commun* 2010, 40, 303.
- [24] The crystallographic data have been deposited at the Cambridge Crystallographic Data Center (E-mail: deposit@ccdc.cam.ac.uk). The deposition number is CCDC-759540.
- [25] Shi, Y. X.; Yuan, L. P.; Zhang, Y. B.; Li, B. J. *Chin J Pest Sci* 2007, 9, 126.